Scott Robinson. "First-in-class TMBIM6 therapeutics: Overcoming limitations in current oncology therapies through ERAD-II induced paraptosis.." Journal of Clinical Oncology (2025). https://doi.org/10.1200/jco.2025.43.16_suppl.e15120